ArticleVaccine2010
A novel adjuvant for vaccine development in the aged.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Article
- The impact of immuno-aging on SARS-CoV-2 vaccine development.GeroScience · 2021Review
- Targeted Amino Acid Substitution Overcomes Scale-Up Challenges with the Human C5a-Derived Decapeptide Immunostimulant EP67.ACS infectious diseases · 2020Article
- Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.Clinical immunology (Orlando, Fla.) · 2015Article
- Age-dependent dysregulation of innate immunity.Nature reviews. Immunology · 2013Review
- Characterization and optimization of the glucan particle-based vaccine platform.Clinical and vaccine immunology : CVI · 2013Article
- Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Novel strategies to enhance vaccine immunity against coccidioidomycosis.PLoS pathogens · 2013Article
- Article
- Progress Toward a Human Vaccine Against Coccidioidomycosis.Current fungal infection reports · 2012Article
- An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection.Vaccine · 2012Article
- Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.PloS one · 2012Article
- Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide.Vaccine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
A conformationally-biased, response-selective agonist of human C5a(65-74) (EP67) activated antigen presenting cells (APC) from aged C57Bl/6 mice in vitro and the generation of antigen (Ag)-specific antibody (Ab) responses in aged mice in vivo. EP67, induced the release of the pro-inflammatory cytokines IL-6, TNFα, and INFγ from splenic APCs obtained from both aged and young mice. Both aged and young mice produced high Ag-specific IgG Ab titers when immunized with EP67-containing vaccines to ovalbumin (OVA-EP67) and to a protein (rPrp1) from the cell wall of Coccidioides (rPrp1-EP67). Immunization with EP67-containing vaccines resulted in higher IgG titers in both young and aged mice compared to mice immunized with OVA adsorbed to alum (OVA/alum) and Prp1 admixed with CpG (rPrp1 +CpG). Aged and young mice immunized with the EP67-containing vaccines generated higher titers of IgG1 and IgG2b relative to their aged-matched counterparts immunized with OVA/alum or Prp1 +CpG. These results indicate that EP67 induces humoral immunity in aged mice not obtainable with alum and CpG. These results support the use of EP67 as a potential vaccine adjuvant suited to the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.